The global breast cancer therapeutics market is experiencing significant growth, driven by the increasing prevalence of breast cancer and advancements in treatment options. As one of the most commonly occurring cancers worldwide, breast cancer necessitates effective and efficient therapeutic solutions to improve patient outcomes.

In 2019, the global breast cancer therapeutics market size was valued at USD 21.58 billion and is expected to grow to USD 55.27 billion by 2027, reflecting a compound annual growth rate (CAGR) of 13.1%. North America led the market, accounting for 47.91% of the global share in 2019.

Top Companies in the Market

• Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)
• Eli Lilly and Company (Indianapolis, U.S.)
• Novartis AG (Basel, Switzerland)
• AstraZeneca (Cambridge, U.K.)
• Pfizer Inc. (New York City, U.S.)
• Sanofi (Paris, France)
• Eisai Co. Ltd. (Tokyo, Japan)
• Kyowa Kirin (Tokyo, Japan)
• Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)
• Merck & Co., Inc. (Kenilworth, U.S.)
• Other Players

Key Industry Development

September 2020: Natco Pharma announced that its marketing partner, Lupin, launched Lapatinib Tablets, 250 mg, in the U.S. after Natco received final approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (USFDA). Natco was the first ANDA applicant for Lapatinib Tablets, 250 mg, containing a Paragraph IV certification.

Market Drivers

• Increasing Prevalence of Breast Cancer: The rising number of breast cancer cases globally is a significant driver for the market. Improved diagnostics and heightened awareness have led to more patients being diagnosed and seeking treatment.
• Advancements in Therapeutic Options: Continuous research and development efforts have led to the introduction of advanced therapies, including targeted therapies and immunotherapies, offering better treatment outcomes.